r/HerpesCureResearch

Preliminary results of the BNT163 BioNTech vaccine.

Pesquisar isso no Google

"There is no licensed HSV-2 vaccine. We developed nanoparticles displaying the HSV-2 attachment protein gD and fusion mediation protein complex gH/gL.

Immunization of mice and non-human primates elicited high levels of neutralizing antibodies. Vaccination conferred robust protection in mice, preventing disease and nearly eliminating infection and shedding following HSV-2 challenge.

While gD induced high neutralizing antibody titers, gH/gL contributed substantially to protection despite lower neutralization titers. Instead, gH/gL immunization generated strong fusion-blocking responses which were an important correlate of protection, showing that standard neutralization assays incompletely capture the importance of fusion-blocking activity.

These findings demonstrate that targeting both HSV-2 attachment and fusion elicit complementary mechanisms for protection from infection and that neutralizing antibody alone may be insufficient for protection. Overall, these results present an innovative strategy for an HSV-2 vaccine."

Your trial guy is back again! These results are 9 days old:

• The first episode of herpes labialis was delayed in BCG-vaccinated children (p = 0.08).
• 38% relative risk reduction of ever having herpes labialis in BCG-vaccinated children (p = 0.1).
• 53% lower risk of herpes labialis recurrence in BCG-vaccinated children (p = 0.02).
• BCG's immunomodulatory effects may help combat HSV, addressing a gap in preventive strategies.

Recently, Alfasigma contacted me to participate in a clinical trial for their new treatment, IM-250. Unfortunately, my current situation does not allow me to participate.

If you’ve read my other posts, you know that I actively fight for herpes awareness and for better recognition of the real impact this virus has on people’s lives.

That is why I am reaching out to everyone. I want to bring people together and show that this virus truly affects millions of lives.

If anyone would like to take my place or receive more information, I would be happy to connect you with the company.

Please share and help make our voices heard.

Hello Everyone,

Please feel free to post any comments and talk about anything you want on this thread--relating to HSV or otherwise.

Have a nice weekend.

- Mod Team

Herpes simplex virus type 2 (HSV-2) is the principal cause of genital herpes, establishes lifelong latency with recurrent mucosal lesions, and facilitates acquisition of human immunodeficiency virus type 1 (HIV-1).

Because current therapy still relies largely on nucleoside analogues and resistant isolates continue to emerge, alternative antiviral strategies are needed.

In this study, halofuginone (HF), a halogenated analogue of the febrifugine scaffold, inhibited both wild-type and acyclovir-resistant HSV-2 in cultured cells at nanomolar concentrations.

In a murine genital challenge model, topical administration before viral exposure reduced viral burden and alleviated local inflammatory responses.

Pre-exposure experiments further showed that HF decreased the infectivity of extracellular HSV-2 particles and was associated with virion structural damage, whereas docking analysis suggested a possible interaction with glycoprotein D (gD). In parallel, partial reversal by L-proline supported a host-cell component linked to inhibition of the prolyl-tRNA synthetase (ProRS) domain of glutamyl-prolyl-tRNA synthetase (EPRS).

HF also suppressed HSV-2-induced activation of the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) axis and the nuclear factor kappa B (NF-κB) pathway.

Beyond HSV-2, HF remained active against herpes simplex virus type 1 (HSV-1) and C-C chemokine receptor type 5 (CCR5)-tropic HIV-1 and retained antiviral activity in an HSV-2/HIV-1 co-infection model.

Overall, the data support a two-component antiviral effect of HF, involving extracellular impairment of viral particles together with intracellular host-directed restriction, and warrant further evaluation of HF as a topical prevention-oriented candidate against HSV-2.

HSV-2 is the leading cause of genital herpes. Resistance to acyclovir is a growing concern.

Stapled peptide SPep7B, originally developed as a potential antiviral against HSV-1 for treating human herpes ocular keratitis, has the extended ability to target HSV-2 replication in vitro and block HSV-2 infection in three-dimensional (3D) human vaginal cells.

We also demonstrate that SPep7B exhibits low cytotoxicity, non-mutagenicity, remarkable metabolic stability in plasma, and the ability to penetrate epithelial tissue.

Together, these findings support the potential of SPep7B as a topical treatment for HSV-2 genital herpes.

Hello Everyone,

Please feel free to post any comments and talk about anything you want on this thread--relating to HSV or otherwise.

Have a nice weekend.

- Mod Team